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Pediatric hepatic angiosarcoma (PHAS) is extremely rare, with only ﬁve reported tumor-free survivors.
Aggressive surgical resection and chemotherapy have been the management in all documented survivors
of this disease, however no speciﬁc treatment guidelines are established. We present a case of PHAS with
the longest reported tumor-free survival at over six years off therapy.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Case report
A previously healthy three-year-old girl presented with right-
sided abdominal pain and general malaise. Her past history was
unremarkable and there were no known environmental exposures.
Physical exam demonstrated tachypnea and hepatomegaly and
ultrasound revealed a hepatic mass. Contrast computed tomography
(CT) scan conﬁrmed a heterogeneous mass measuring
13.8  12.8  14.1 cm, involving nearly the entire right lobe with
effacement of the renal vein and IVC adjacent to the mass (Fig. 1).
There was no evidence of metastatic disease. Laboratory values,
including alpha feto-protein, were within normal limits. Due to the
proximity of the mass to the portal vein, it was initially considered
unresectable, and she underwent ultrasound-guided biopsy of the
mass with port placement for expected neo-adjuvant chemotherapy.
The biopsies demonstrated an endothelial neoplasm consistent with
PHAS. Thehistopathologic featureswere similar to thoseencountered
in the resection specimen described below. With no proven chemo-
therapy for PHAS, treatment with Paclitaxel and Bevacizumab was
initiated with informed consent based on use in the adult angio-
sarcoma population. The ﬁrst course consisted of Paclitaxel alone toan 3, 300 Longwood Avenue,
1 617 730 0316.
(H.B. Kim).
Inc. This is an open access article umonitor tolerance, as there were no pediatric trials combining the
agents. Paclitaxel was tolerated, but because the mass had remained
radiographically stable in the week following diagnosis, complete
resectionwas recognized as the best chance for survival. Threeweeks
after presentation, the patient underwent right hepatic tri-
segmentectomy. Intraoperative frozen sections demonstrated a close
margin anterior to the portal vein plate necessitating additional
resection to the extent deemed safe. Final pathology demonstrated
viable tumor over a 1 cm area at this margin. The patient was dis-
charged home postoperatively without complication.
Chemotherapy began ten weeks postoperatively, after patho-
logic conﬁrmation of the diagnosis and a restaging CT scan. The six-
month course included six 28-day cycles of Paclitaxel 50 mg/m2
(days 1,4,8,11,15 and 18), and Bevacizumab 10 mg/m2 IV (days 1 and
15). Serial CT and magnetic resonance imaging (MRI) throughout
chemotherapy treatment did not yield evidence of tumor recur-
rence. Following chemotherapy, she was monitored with serial MRI
every three months for two years and then alternating ultrasound
or MRI every three months to date. Most recently, over six years off
therapy, there is no evidence of tumor recurrence.1.1. Pathology
A 15  11  10 cm circumscribed, non-encapsulated mass
extended to the resection margin superior to the portal vein. Thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Contrast CT scan at presentation demonstrating a large heterogeneous mass
involving most of the right hepatic lobe.
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hemorrhage up to 3 cm in diameter (Fig. 2A). Histopathologically,
most of the tumor demonstrated short fascicles of spindled
endothelial cells (EC) with peripheral strands of biliary epithelium
unrelated to portal tracts (Fig. 2B). Atypical ECs were spindled
(kaposiform) with lightly eosinophilic cytoplasm and enlarged
nuclei with coarsened chromatin and small nucleoli. The lumens
were inconspicuous (Fig. 2C). Other areas showed expanses of
solid aggregates of ECs with more pleomorphic vesicular nuclei,
larger nucleoli, and apoptosis (Fig. 2D and E). Another pattern was
anastomotic widened channels with papillations and endothelial
redundancy (Fig. 2F). Occasional ECs contained eosinophilic
cytoplasmic inclusions staining positive with the periodic acid-
Schiff stain. Infrequent vascular invasion was limited to small
veins. Peripherally, layered spindled ECs replaced normal sinu-
soids (Fig. 2G). Several sections showed a few small foci with small
channels with ﬂattened bland endothelium (Fig. 2H). Occasional
mitoses were observed but a precise mitotic count was difﬁcult to
ascertain because of apoptosis. The proliferation marker, MIB-1,
showed an index of up to 25% in the EC population within “hot
spots.” Immunostaining showed lesional EC throughout the tumor
were positive for CD31, CD34, LYVE-1, and Glut-1 and negative for
D2-40 and Prox-1. Cytogenetic analysis of mitotic cells from 7 to 10
day cultures of tumor samples revealed a normal karyotype.2. Discussion
PHAS is a rare pediatric hepatic vascular tumor, with fewer than
50 reported cases. It occurs twice as often in girls, and the reported
age at diagnosis is twomonths to ﬁfteen years [1]. To date, there are
only ﬁve reported cases of disease-free survival in PHAS [2e6].Although environmental exposures have been linked to adult he-
patic angiosarcoma, only one case of PHAS has been potentially
linked to arsenic exposure [7], as these chemicals require several
years of exposure prior to tumor detection [8]. Associated signs and
symptoms include jaundice, abdominal pain, vomiting, fever,
tachypnea, and dyspnea, and those related to lung, bone, lymphatic,
adrenal, or renal metastases [4]. Accurate diagnosis requires biopsy
because clear, reliable, distinguishing radiographic features be-
tween PHAS and benign tumors are not always present [9]. While
PHAS may be histopathologically indistinguishable from adult he-
patic angiosarcoma, it usually has a characteristic component of
hypercellular fascicles and whorls of atypical spindled endothelial
cells and cytoplasmic eosinophilic globules [3,10,11]. However, a
diagnosis of PHAS is almost always challenging because PHAS can
have regions of small channels with bland or only minimally
atypical endothelium [3,12] thereby mimicking hepatic infantile
hemangioma (solitary, multifocal or diffuse types according to the
Hepatic Tumor Registry Classiﬁcation) [13,14], or reactive vascula-
ture around another tumor; thus limited sampling of a lesion may
be inconclusive or misleading (personal observation, HK).
Furthermore, some hepatic hemangiomas, particularly of the
multifocal or diffuse type, have papillation with endothelial
redundancy or pleomorphism that may be extremely difﬁcult to
distinguish from PHAS (personal observation, HK). Many patholo-
gists diagnose atypical hepatic vascular tumors that don’t reach the
level of an obvious angiosarcoma as infantile hemangioendothe-
lioma type 2 as described by Dehner and Ishak [15]. As opposed to
their histopathologically benign-appearing infantile hemangioen-
dothelioma type 1 category, category type 2 is more aggressive-
appearing with branching vascular structures, irregular budding
and tortuous vascular spaces lined by larger and more hyper-
chromatic and pleomorphic endothelial cells. Some observors have
chosen to regard infantile hemangioendothelioma type 2 as
angiosarcoma [10]. In our experience, in infants who have diedwith
extensive multifocal or diffuse hepatic hemangioma (probably
equivalent to infantile hemangioendothelioma type 2 on the
aggressive end of the spectrum), there has usually been a lesser
degree of pleomorphism and mitotic activity and the solid spindled
areas (often called kaposiform), if present, were small and widely
dispersed as compared to PHAS. Nevertheless, the distinction be-
tween hepatic hemangiomas particularly of the multifocal or
diffuse types, infantile hemangioendothelioma type 2, and PHAS
can be difﬁcult if not impossible on needle biopsies and sometimes
even at autopsy because of overlapping features and because the
criteria cited above are subjective to some degree. Additionally,
there may be a reluctance on the part of the pathologist to make an
outright diagnosis of malignancy because of therapeutic implica-
tions, particularly hepatic transplantation in some cases. It should
also be emphasized that a vascular lesion encountered during in-
fancy but failing to regress within two years of age or a vascular
lesion discovered after the age of two should be viewed with
extreme suspicion because of the possibility of it being a PHAS.
PHAS often presents as a large tumor, making resection difﬁcult
[3]. Although the literature is limited, it appears that aggressive
surgical resection offers the best chance for survival. Limited re-
ports on liver transplantation for PHAS have had mixed results, but
have resulted in survival for some patients [5,6,9]. In our patient,
liver transplantation was considered both preoperatively and after
return of the microscopic positive margin after resection. However,
given the certainty of the diagnosis by biopsy and the overall poor
prognosis of PHAS, it was decided to proceed with an attempt at
resection since we believed we could achieve a total gross resection
with an extended right hepatectomy.
The average documented survival for PHAS is less than 16
months [9]. The ﬁve tumor-free survivors described in the literature
Fig. 2. Gross specimen with tumor and necrotic foci (A). Histopathology: tumor nodules (B); “spindled kaposiform” endothelial cells (EC’s) (C); enlarged nuclei and prominent
nucleoli (D); pleomorphic ECs with apoptosis (E); rounded, crowded ECs (F); EC layers separate hepatocyte cords (G). (H) demonstrates small channels, ﬂattened endothelium and
bland nuclei. EC ¼ endothelial cell.
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however, there are no agreed upon treatment guidelines. This is the
ﬁrst report of chemotherapy with Paclitaxel and Bevacizumab for
PHAS. A variety of regimens reported in PHAS management have
been based on protocols for sarcoma treatment. These have not
proven to be efﬁcacious and are known to have numerous side ef-
fects. Anecdotal experience, however, does exist to support the use
of taxanes in adult angiosarcomas [16,17]. The use of vascular
endothelial growth factor (VEGF) inhibitors has been explored in
patients with sarcomas and was especially compelling in the
treatment of angiosarcoma given the high rate of VEGF expression
in these tumors [18]. In adults, a Phase III study of Paclitaxel/Bev-
acizumab in metastatic breast cancer and a Phase II study
comparing Bevacizumab plus Carboplatin and Paclitaxel with Car-
boplatin and Paclitaxel alone demonstrated the potential advantage
of this combination in refractory solid tumors [19,20]. Furthermore,
Phase I studies of each individual drug in children showed that both
drugs were relatively well tolerated, with toxicity almost exclu-
sively limited tomyelosuppression. We therefore decided to use the
combination of Paclitaxel/Bevacizumab in this patient with PHAS,
and utilize traditional sarcoma-based therapy for disease progres-
sion and/or unacceptable toxicity from the novel regimen. The
patient tolerated the chemotherapy extremely well with no acute
toxicities. Six years off therapy, she has no evidence of disease
recurrence and has had no evidence of complications of treatment
such as growth disturbance, cardiac toxicity or developmental
issues.3. Conclusion
In summary, aggressive surgical resection should be performed
in patients with PHAS to optimize outcome. Post-operative adju-
vant chemotherapy using Paclitaxel and Bevacizumab should be
considered for patients even after complete gross resection given
the historically poor outcomes in patients with PHAS. If this
chemotherapy regimen proves to be efﬁcacious in PHAS, more
aggressive modes of liver resection including liver transplantation
may be entertained in the future.
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